Skip to main content
SpringerLink
Log in

Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–58.

    Article  PubMed  CAS  Google Scholar 

  2. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.

    Article  PubMed  Google Scholar 

  3. Haller D, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur J Cancer Suppl. 7(3)3:4

  4. Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010; doi:10.1245/s10434-009-0881-y.

  5. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. Sep 19 1990;264(11):1444–50.

    Google Scholar 

  6. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294(21):2703–11.

    Article  PubMed  CAS  Google Scholar 

  7. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–97. PMID:11596588.

    Article  PubMed  CAS  Google Scholar 

  8. Sargent DJ, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–7.

    Article  PubMed  Google Scholar 

  9. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25(29):4569–74.

    Article  PubMed  Google Scholar 

  10. Sargent DJ, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, et al., The Adjuvant Colon Cancer Endpoints (ACCENT) Group. Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. J Clin Oncol. 2009;27:15s, (suppl; abstr 4011).

    Google Scholar 

  11. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.

    Article  PubMed  CAS  Google Scholar 

  12. Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O’Connell MJ, Yothers G. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol. 2008;26:(May 20 suppl; abstr LBA4005).

  13. Wolmark N, Yothers G, O’Connell MJ, Sharif S, Atkins JN, Seay TE, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009;27:18s, (suppl; abstr LBA4).

    Google Scholar 

  14. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1995;17:1349–55.

    Google Scholar 

  15. IMPACT Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939–44.

    Article  Google Scholar 

  16. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–29.

    Article  PubMed  CAS  Google Scholar 

  17. Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery IC, et al., Quasar Colon Teams. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol. 2009;27:15s, (suppl; abstr 4000).

    Google Scholar 

  18. Roth AD, Tejpar S, Yan P, Fiocca R, Klingbiel D, Delorenzi M, et al. Correlation of molecular markers in colon cancer with stage-specific prognosis: Results of the translational study on the PETACC3 – EORTC 40993-SAKK 60-00 trial. ASCO GI Cancer Symp Abstr. 2009;288.

  19. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New Engl J Med. 2003;349:247–57.

    Article  PubMed  CAS  Google Scholar 

  20. Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol. 2008;26: (May 20 suppl; abstr 4008).

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA

    Daniel Sargent PhD

  2. Department of Oncology, Mayo Clinic, Rochester, USA

    Axel Grothey MD

Authors
  1. Daniel Sargent PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Grothey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Sargent PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sargent, D., Grothey, A. Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. Ann Surg Oncol 17, 947–949 (2010). https://doi.org/10.1245/s10434-009-0880-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0880-z

Search

Navigation